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ABSTRACT
OBJECTIVE: The objective of this selective evidence based medicine review is to determine
whether or not “Are PRP injections effective at decreasing chronic low back pain in adults?”
STUDY DESIGN: Systematic review of two randomized control trials and one prospective
clinical evaluation written in English, published after the year 2012.
DATA SOURCES: All three articles were found in peer review journals published via PubMed
Database.
OUTCOME MEASURED: The primary outcome measured in each study is self-reported pain
at baseline and 4 weeks following injection of PRP or the comparison. The visual analog scale
and a generic numeric rating scale were used to measure pain.
RESULTS: 1 of the 3 studies found PRP injections to be statistically effective at decreasing low
back pain in adults at the time period assessed. Wu et al found that, at 4 weeks post injection,
pain scores on a scale of 0 to 10 were on average 3.84 points less when compared to baseline
scores (p<0.05) and were significantly lower at all other time points as well (Pain physician.
2016;19(8):617. https://www.ncbi.nlm.nih.gov/pubmed/27906940). Singla et al found no
significant difference in pain levels at 4 weeks post injection when compared to the steroid
control group but found a 75% reduction in VAS at 4 weeks when compared to baseline scores
(Pain practice: the official journal of World Institute of Pain. 2017;17(6):782-791.
https://www.ncbi.nlm.nih.gov/pubmed/27677100. doi: 10.1111/papr. 12526). The TuakliWosornu et al study also revealed no significant difference in pain at 4 weeks when compared to
baseline (p=0.215), but participants did have significant improvement regarding pain, function,
and patient satisfaction over 8 weeks (PM R. 2016;8(1):1-10.
https://ezproxy.pcom.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=jlh
&AN=112177067&site=eds-live&scope=site. doi: 10.1016/ j.pmrj.2015.08.010).
CONCLUSIONS: This review finds conflicting evidence that PRP injections are more effective
than other treatment for chronic low back pain. The 2 RCTs did not show significant decrease in
pain at the 4 week follow up time assessed, and the remaining study had severe limitations.
Regardless, all three studies did show statistically significant improvement by the end of each
study, so this review finds stronger evidence to support PRP injections for adjunctive use in
adults with chronic low back pain.
KEY WORDS: Lumbar OR lower back, PRP OR platelet-rich plasma
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INTRODUCTION
An estimated 84% of adults have low back pain at some point in their lives.1 Most cases
are self-limiting and resolve within 6 weeks.1 Chronic low back pain is defined as pain persisting
longer than 12 weeks.2 The cause is often multifactorial and difficult to diagnose. Intervertebral
discs are the origin of 40% of reported back pain and are the largest avascular structure in the
human body, contributing to the disc’s inability to regenerate and heal. 3 Facet joints are synovial
joints of the spine that, with overuse and injury, can degenerate and cause a release of
inflammatory mediators, capsular stretch, entrapment of synovial villi between articular surfaces,
and nerve impingement by osteophytes.4 Nearly 15-52% of patients have low back pain caused
by lumbar facet joint syndrome.4 The sacroiliac joint has been found to be the primary point of
pain in 10% to 27% of adults with chronic low back pain, usually owing to injury.5 Back injuries
are more common in patients younger than 45, and disc disorders increase in frequency as the
population ages.6
Secondary only to skin disorders, low back pain is one of the most common reasons
people visit their primary care provider. In 2013 there were an estimated 62 million visits to
hospitals, emergency departments, outpatient clinics, and physician offices,6 and costs estimated
at $87.6 billion make low back pain the third largest condition of health care spending.7 These
statistics do not include visits to chiropractors and physical therapists.
For patients with chronic low back pain, management can be a lengthy and trial-by-error
process. Initially, patients are encouraged to utilize nontherapeutic treatments such as stretching,
exercise, and heat application, as well as psychological therapies such as CBT and biofeedback.1
Adjunctive therapies for short-term management of symptoms include spinal manipulation,
acupuncture, or massage.1 For more severe pain symptoms, pharmacologic therapy is used along
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with nonpharmacologic measures.1 Non-steroidal anti-inflammatory drugs (NSAIDs) are first
line, and if contraindicated acetaminophen is recommended. 1 If these are ineffective, duloxetine,
tramadol, cyclobenzaprine, and epidural injections may be utilized.1 Neuropathic pain can be
treated with alpha-2-delta ligands such as gabapentin.7 Surgery, although unlikely to cure low
back pain, can improve pain levels. Surgical indications include cauda equina syndrome, cancer,
infection, severe spinal deformity, or persistent morbidity despite treatment with conservative
measures for 6 months.7
Although the above treatments have some proven efficacy when compared to
placebo in clinical trials, chronic low back pain continues to decrease the quality of life for
millions of Americans. Platelet rich plasma (PRP) has been shown to be effective in treating
many different musculoskeletal disorders and may be used as combination therapy with the
above treatments, leading to improvement in quality of life. PRP consists of a high concentration
of platelets derived from the patient’s own peripheral venous blood. PRP is composed of
bioactive proteins that influence the healing of tendons, ligaments, muscles, and bones; as well
as growth factors and cytokines including platelet-derived growth factor, transforming growth
factor-B, fibroblast growth factor, insulin-like growth factor 1, connective tissue growth factor,
and epidermal growth factor.4 These components work to promote cell proliferation, matrix
regeneration, and angiogenesis. Growth factors and cytokines injected at a high concentration
directly at the site of collagen injury or degeneration can act as humoral mediators to induce the
natural healing cascade. In addition, they produce an anti-inflammatory effect and lab studies
indicate that PRP possesses antimicrobial properties that contribute to a decreased risk of
infection.5 PRP has been shown in previous studies to be effective at reducing pain and
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functional disability in conditions such as tennis elbow, knee osteoarthritis, achilles
tendinopathy, and chronic patellar tendinosis.5
Physician assistants are likely to encounter patients with chronic low back pain regardless
of their chosen specialty. Given the method of administration, affordability, and accessibility,
PRP is a treatment option deserving closer consideration.
OBJECTIVE
The objective of this selective evidence based medicine review is to determine whether or
not “Are PRP injections effective at decreasing chronic low back pain in adults?”
METHODS
This review evaluates three peer-reviewed articles that assess the efficacy of PRP in
reducing chronic low back pain. Two studies used control injections for comparison: contrast 3
and methylprednisolone with lidocaine and saline.5 The three studies include a prospective
clinical trial; a prospective, double blind randomized control study; and a prospective
randomized open blinded end point study that have not been previously used in a systematic
review or meta-analysis. Participants were 18 years of age or older with diagnosed chronic low
back pain. See Table 1 for specific inclusion and exclusion criteria for each individual study.
Pain intensity was assessed before and after administration of PRP or the control agent at
different time intervals. Each article reported pain evaluated at different intervals and reported
pain accordingly. This paper will focus on the pain reports collected prior to intervention and 4
weeks post-injection. The statistics used to evaluate pain intensity are mean pain scores with
standard deviation, paired t-test, and p-values.
Key words used to search for the studies were “low back OR lumbar”, and “PRP OR
platelet rich plasma”. Each article was published in English and found via PubMed database with
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the inclusion criteria of publication after the year 2012 and randomized controlled trials. Only
two randomized controlled trials were identified that matched these criteria, so the prospective
clinic evaluation was selected based on its relevance to the objective. All three articles were
selected based on patient oriented outcomes. Exclusion criteria included patients under the age of
18 and those with acute low back pain.
TABLE 1: Demographics & Characteristics of Included Studies
Study

Type

Age
(yrs)
18-65

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

RCT

# of
Pts
40

Singla1
(2017)

Patients >18 with
chronic low back pain
of moderate intensity
for >3 months;
unilateral SIJ pathology
on XR, MRI or nuclear
scan with 3 or more +
provocative tests.

0

3mL of PRP
with 0.5mL of
calcium
chloride into
ultrasound
guided SIJ
injection

RCT

47

>18
yrs

Refractory low back
pain for >6 months;
failure of conservative
treatment; maintained
intervertebral disk
height of at least 50%;
disk protrusion <5mm
on MRI or CT;
concordant pain on
diskography; presence
of a grade 3 or 4
annular fissure; absent
CI

Systemic or
localized infection;
spinal path that
might impede
recovery; history of
intervertebral disk
disease; pregnancy;
active radicular
pain;
immunosuppressive
conditions; allergy
to medications used;
narcotic use, CI
pertaining to the use
of platelet
concentrate.
Presence of known
bleeding disorder;
current
anticoagulation
therapy; pregnancy;
systemic or local
infection; allergy to
contrast agent;
psychiatric
condition; solid
bone fusion
preventing access;
severe spinal canal
compromise;
extrusions or
sequestered disk
fragments; previous
spinal surgery;
spondylolysis;
spondylolisthesis;
discordant pain on
diskography;
presence of grade 5
annular fissure

TuakliWosornu2
(2016)

4

1-2mL
injection of
autologous
PRP into
symptomatic
degenerative
intervertebral
disks.
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Wu3
(2016)

Prospective
clinical
evaluation

19

38-62

Continuous or
intermittent low back
pain; local or paraspinal
pain with or without
radiation, increase of
pain on flexion,
rotation, or lateral
bending, absence of
neuro deficit, XR
showing findings of
lumbar facet joint
degenerative changes

Radicular neuro
complaints or with
evident disc
herniations, prior
surgery on the spine,
intolerance of local
anesthesia and
contrast media

0

Injection under
fluoroscopy of
1-2mL of
autologous
PRP after
injection of
0.5% lidocaine
and nonionic
contrast was
administered
locally.

OUTCOMES MEASURED
The outcome measured in all three studies was the self-reported pain score of patients 4
weeks after PRP injection, evaluated using the Visual Analog Scale (VAS) or Numeric Rating
Scale (NRS). Both require the patient to rate their pain based on a 0 to 10 scale, with 0 being no
pain and 10 being the worst pain imaginable.
RESULTS
The prospective clinical evaluation by Wu et al included 8 men and 11 women with
diagnosed lumbar facet joint pain who failed other interventions for at least 3 months prior to the
study.4 Exclusion criteria included evident disc herniations and prior surgery, because these were
identified as independent variables that affect pain relief after intra-articular facet joint
injections.4 A CBC was performed on the patient’s peripheral blood before treatment and on the
centrifuged PRP to ensure the platelet concentration in the PRP was about 4 to 5 times greater
than that in the native peripheral blood. Patients were injected with approximately 1-2 mL of
autologous PRP under fluoroscopy by a spine surgeon. There was no control injection group. No
complications were observed throughout the procedures.4 Participants were instructed to rest and
not to bend at the waist for one week. The results state that patients were given pain relief
information and that “there was no anti-inflammatory treatment for patients during the 3 month
follow-up period”, suggesting that patients could not take NSAIDs at home. 4 The VAS was
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conducted immediately following treatment and at 1 week, 1 month, 2 months, and 3 months
post-procedure. The mean VAS scores for low back pain at rest were 7.05 before treatment and
3.21 at 4 weeks (Table 2).4 A p-value of < 0.05 was calculated using the SPSS version 19.0
program.4
Table 2: Mean VAS Pain Scores at baseline and 4 weeks in Wu et al
Baseline
4 weeks post-op
Mean
7.05
3.21
P-value
<0.05
Singla et al conducted a prospective randomized open blinded end point study that
included 40 patients with chronic low back pain who were previously diagnosed with sacroiliac
joint (SIJ) pathology.5 Patients had unilateral SIJ pathology on imaging with baseline VAS
scores of greater than 3 for at least 3 months.5 Patients on greater than 60 mg of morphine
equivalent doses of opioids were excluded due to their altered pain responses. The participants
were allocated into 2 groups randomly by computer-generated numbers and the sequence was
placed into sealed, opaque envelopes. Both the patients and investigators were blinded to the
injectant given at the time of the procedure. There were no significant differences in the baseline
parameters between the two groups. Under guidance of ultrasound, the comparison group (Group
S) received 1.5 mL of methylprednisolone with 1.5 mL of 2% lidocaine and 0.5 mL of saline
while the treatment group (Group P) received 3 mL of PRP with 0.5 mL of calcium chloride.5
There were no major complications.5 The mean platelet content in the PRP was 2.94 + 1.43.5 All
pain medication including NSAIDs were discontinued for the duration of the study, but those
with diagnosed ankylosing spondylitis continued Sulfasalazine therapy. Patients were followed
up at 2 weeks, 4 weeks, 6 weeks, and 3 months for assessment of pain intensity using the VAS.
The percent change in score from baseline calculation formula was provided. Data was compared
between the 2 groups using the Mann-Whitney U-test, and the follow up VAS scores were
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compared to baseline with post hoc analysis using Bonferroni correction. 5 All patients were
analyzed in the groups to which they were randomized, and none were lost to follow up. The
median VAS scores for Group P were 7.5 and 1.5 at pre-injection and 4 weeks, respectively.5
The median VAS score for Group S went from 6 pre-injection down to 3 at 4 weeks.5 According
to the calculated p-values, there was no statistically significant difference between groups at
either time period. At 4 weeks, 75% of patients in Group P and 70% of patients in Group S had a
reduction in VAS > 50%, with a p-value of 0.723.5 Therefore, there was no significant difference
in patients having > 50% reduction in VAS score at 4 weeks among the two groups.5
Table 3: Median VAS Pain Scores at baseline and 4 weeks in Singla et al
PRP Group
Steroid Group
(n=20)
(n=20)
Median (Interquartile Range)
7.5 (5-8)
6 (5-7)
at baseline
Median (Interquartile Range)
1.5 (1-3)
3 (2-4)
at 4 weeks
Reduction in VAS at 4 weeks
75% (15)
70% (14)

P-value
0.132
0.054
0.723

The randomized controlled study performed by Tuakli-Wosornu et al included 47
participants with chronic axial low back pain, diagnosed via discography.3 A total of 109
participants were assessed for eligibility from 2009 to 2013 at an academic outpatient spine
practice. Fifty-eight were chosen and randomized for inclusion into the study. After discography,
7 were disqualified based on exclusion criteria, 3 failed to maintain inclusion and exclusion
criteria throughout, and 1 was lost to follow up. 3 Notable exclusion criteria include disk
protrusion >5 mm because targeted annular therapy would likely be to no avail, and grade V
annular fissures because the injectate would likely flow out of the disk into the epidural space,
lessening the opportunity for the PRP to have an effect. 3
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About 2 weeks prior to treatment baseline blood samples were taken to assess blood
counts, ESR, and PT/INR to ensure they were within normal limits. Randomization was
performed by an independent observer who drew cards from a sealed envelope to form a
treatment and control group with a 2:1 ratio, respectively. There was a significantly greater
number of females randomized to the control group than the treatment group, but other
demographics were not significantly different. 3 During injection of 1-2 mL of either PRP or a
contrast agent, the syringe was covered with an opaque sleeve to ensure that contents were not
visible to the physician or the patient. There were no reported complications. 3 All participants
were followed with questionnaires at designated time points for one year, and a subset was
followed for up to 2 years. If a participant did not meet a minimal clinically significant outcome,
they were unblinded at 8 weeks and offered intradiscal PRP if they were part of the control
group. The NRS is commonly presented as a 100 mm horizontal line on which pain intensity is
labeled from 0 to 10. Differences in mean PRP group scores at follow up time points compared
with those at baseline were assessed using paired t-tests. Measures of the association between
groups were calculated using odds ratios with observed level of significance determined by
Pearson X2 test. Mean NRS score at baseline was 4.61 and 4.74 for the control and PRP groups,
respectively.3 At 4 weeks, mean NRS score was still 4.61 for the control group and dropped to
4.0 for the PRP group.3 The p-value of 0.157, however, reveals an insignificant change between
the two groups.
Table 4: Median VAS Pain Scores at baseline and 4 weeks in Tuakli-Wosorni et al
PRP Group
Control Group
(n=29)
(n=18)
Mean + SD at baseline
4.74 + 2.21
4.61 + 2.21
Mean + SD at 4 weeks
4.00 + 2.21
4.61 + 2.21
P-value
0.215
0.157
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The safety of sterile PRP injections was revealed throughout all three studies based on the
lack of serious complications. Singla et al found that pain and stiffness post injection was higher
in Group P when compared with Group S, but the symptoms were transient, local, and mild in
nature.5 These symptoms are thought to be due to the stimulation of the body’s natural response
to inflammatory mediators rather than the injection technique. 5
Table 5: Adverse Events Reported in PRP Groups
Study
PRP Group Size
Singla et al 4

20

Adverse Event
Post injection pain and stiffness (n=9)
Chest pain and difficulty breathing (n=1)
Contralateral pain (n=1)

DISCUSSION
Wu et al found that participants had an average decrease of almost 4 points in their pain
score rating 4 weeks after PRP injection. 4 Pain scores improved even further by the end of the 3
month follow up period, supporting the effectiveness of PRP for chronic low back pain.
However, lack of comparison with a control group weakens the validity of this study.
In the Singla et al study Group S had a significant increase in pain scores at 3 months as
compared to 2 and 4 weeks, lending to the short-term action of steroids.5 This demonstrates that
anti-inflammatory changes alone are not enough to reduce pain and disability long-term in
patients with SIJ pain. The addition of growth factors enhances the biologic environment and
improves tissue homeostasis. Although the findings were not significant at 4 weeks, the
difference in VAS scores was significantly lower in Group P than Group S at 6 weeks and 3
months.5
Results of the Tuakli-Wosornu et al study revealed no statistically significant
improvement in current pain at 4 weeks post injection when compared with controls.4 However,
over the 8 weeks of follow up there were significant improvements in other measured outcomes:
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best pain, function, and patient satisfaction. Furthermore, those who received PRP reported an
improvement in function through at least one year of follow up.4
Disadvantages of PRP include the variance of composition from subject to subject and
possibly a small amount of growth factors.3 Two of the three studies performed cell content
analysis on the PRP samples, ensuring uniformity and controlling for differences in quality of the
treatment.4,5 All 3 studies had limitations in common including a relatively low number of
participants, making it difficult to apply the results to the general population. None of the studies
reviewed post procedure imaging to assess the effect that PRP had on the individual disease
processes. Doing so would allow for determination of the best candidates for this procedure.
The Wu et al study had many limitations due to the small sample size, lack of a control
group, minimal follow up time of just 3 months, and lack of follow up imaging. 4 There was a
complete lack of information about allowed use of other pain relievers. No labs were completed
and only subjective evidence was taken into consideration.
Singla et al had an important strength unique to all the studies: they controlled the use of
all other pain medication, including NSAIDs, throughout the study.5 Additionally, PRP was
injected under ultrasound guidance, improving accuracy and limiting radiation exposure.
Limitations of this study included a wide variability in the platelet count of PRP, short follow up
time, and they allowed the continued use of sulfasalazine in participants who were diagnosed
with ankylosing sponydlitis.5
The double-blind, randomized, controlled trial design, lengthy and rigorous selection
process for participants, and long-term data were among the strengths of the Tuakli-Wosornu et
al study.3 A limitation was the short follow up time of only 8 weeks for the control group. There
was no data collection on the cell counts or biochemical analysis of the PRP used in this study.
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CONCLUSION
Steroids and other current treatment recommendations have been shown to offer short
term relief of low back pain, but there is still a need to investigate long-lasting treatments that
address the disease process itself. This review evaluated relief of low back pain 4 weeks after
PRP injection and found that 2 of the 3 studies showed no statistically significant improvement
vs the control group,3,5 and the third has substantial limitations discrediting validity.4 However,
each study demonstrated improvement of pain after PRP injection in comparison with the
baseline pain rating, and although this is not statistically significant it could still be clinically
significant. This leads to the conclusion that PRP injections are effective at decreasing chronic
low back pain in adults. PRP resolves the concern of long-term adverse effects of continuous
intra-articular steroid injection and appears to have longer lasting benefits. 5
Future studies should combine the strengths of the studies evaluated in this review. The
use of adjunctive pain medication should be restricted to offer better control. The studies should
be designed with a longer follow-up time frame so that differences between groups over time can
be detected, as well as the duration of action of PRP on different disease processes and patient
populations. This would allow for determination of treatment schedules. It is currently unclear
whether multiple injections improve or worsen outcomes. Follow up should include routine
radiologic studies to objectively guide this process and determine the extent of anatomical
improvement of degeneration and injury as compared with baseline imaging. Administration of
studies meeting these criteria can demonstrate PRP injections to be an affordable, safe alternative
to current treatment options, in addition to improving the disability status of adults with chronic
low back pain.
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